| Plasma Appearance of Xanthohumol in Healthy Adults | Plasmakinetics of Micellar Solubilized Xanthohumol in Metabolically Healthy Men and Women | NCT05524714 |
| Effects of Xanthohumol on Resting Energy Expenditure and Substrate Oxidation in Healthy Women | Effects of Micellar Solubilized Xanthohumol on Resting Energy Expenditure and Substrate Oxidation in Healthy Women | NCT05711212 |
| Xanthohumol As an Adjuvant in the Treatment of Septic Shock | Analysis of Anti-inflammatory Effect of Hop Extract Rich in Xanthohumol in Patients Treated for Septic Shock | NCT06225258 |
| Xanthohumol and Viral Infections (XL) | Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans | NCT06286657 |
| Hop Compounds on the Immune System (VH) | Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System | NCT06286644 |
| Hop Compounds on the Immune System in Overweight People | Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System in Overweight People With the Onset of Metabolic Diseases | NCT06745102 |
| Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients | Humulus Lupus Extract Rich in Xanthohumol Improves Clinical Course in Critically Ill COVID-19 Patients | NCT05463393 |
| A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease | A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease | NCT04590508 |
| Xanthohumol Metabolism and Signature | Xanthohumol Metabolism and Signature (XMaS) in Healthy Adults | NCT03735420 |
| Xanthohumol and Prevention of DNA Damage | Prevention of Oxidative DNA Damage by Xanthohumol | NCT02432651 |
| Xanthohumol and Metabolic Syndrome | Xanthohumol and Metabolic Syndrome | NCT01367431 |
| Hop Compounds and Immune System | Effect of Iso-alpha-Acids and Xanthohumol on Inflammatory Processes in Human | NCT04847193 |
